Boris Duchemann

Sep 1, 2023 | breathe.ersjournals.com | Ana Batalha Oliveira |Thomas Gille |Elena Bargagli |Boris Duchemann

IntroductionSeveral interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), are characterised by progressive fibrosis (figure 1), and share similar disease behaviour, impacts and needs. These diseases lead to limitations in daily activities and social participation due to symptoms such as breathlessness, cough and fatigue. In the past decade, significant improvements have been made in pharmacological therapies, mainly for IPF, which have improved prognosis.